[Question] dose escalation — what am I missing here
Something I noticed reading old threads that I have not seen said out loud.
The advice on TRIUMPH in this community changed substantially around the start of last year, and nobody went back and updated the older posts. So depending on which thread the search engine hands you, you get two contradictory answers with the same confidence.
I have listed what I think the current consensus is below. Correct me — that is the point of posting it.
best — the order this archive was captured in
I am going to push back on this slightly.
the glucagon component changes the side effect profile, not just the efficacy
the glucagon component changes the side effect profile, not just the efficacy
Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.
Crossposting this to c/progresspics because the people who need it are not reading this community.
Are you quoting phase 2 or is there phase 3 data now?
the 15mg arm is different from 0.25mg, results do not transfer
Tracking number removed. It identifies both ends of a shipment.
nobody should be giving this to anyone without extensive monitoring
nobody should be giving this to anyone without extensive monitoring
Disagree on that part. 98.4% and 98.3% on the same vial is normal.
triple agonism plus glucagon is a different physiological state than GIP/GLP-1 dual
Yeah, phase 2 retatrutide is interesting but it is not comparable to phase 3 compounds.
Rodent data is rodent data. Dose scaling is not linear and the models tell you what to investigate, not what to expect.
Dose escalation on retatrutide is steeper and faster than on semaglutide. Do not assume the titration patterns transfer.
Strongly agree. Heart rate escalation needs the actual data, not impressions.
triple agonism is phase 2, do not generalise
Yeah, phase 2 retatrutide is interesting but it is not comparable to phase 3 compounds.
heart rate and dose escalation need actual measurements, not impressions
Strongly agree. Heart rate escalation needs the actual data, not impressions.
Did you actually measure heart rate or is that a feeling?
Yeah, phase 2 retatrutide is interesting but it is not comparable to phase 3 compounds.
triple agonism plus glucagon is a different physiological state than GIP/GLP-1 dual
This is correct. Triple agonism is genuinely different.
What was the dosing schedule in that arm?
research use only, handling and analysis, not protocols
research use only, handling and analysis, not protocols
the weight curves are unusually steep, which makes predicting individual response harder
Strongly agree. Heart rate escalation needs the actual data, not impressions.
Sceptical. If this were true we would see it reflected in the data and we do not.
the glucagon component changes the side effect profile, not just the efficacy
- 1Strongly agree. Heart rate escalation needs the actual data, not impressions.6 comments in this branch · started by u/dead_space_doug
- 2research use only, handling and analysis, not protocols6 comments in this branch · started by u/helga_vermeulen